Trial Profile
Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs RST 001 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Sponsors AbbVie; Allergan
- 10 Nov 2023 Planned End Date changed from 2 Sep 2024 to 23 Sep 2024.
- 09 Sep 2022 Planned End Date changed from 24 Apr 2035 to 2 Sep 2024.
- 24 Mar 2020 Status changed from recruiting to active, no longer recruiting.